Vancomycin Containing PLLA/beta-TCP Controls MRSA In Vitro

Date

2011-11-01

Author

Kankilic, Berna
Bayramlı, Erdal
Kilic, Emine
Dagdeviren, Sezin
Korkusuz, Feza

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

0
views

2
downloads

Osteomyelitis caused by Methicillin-resistant Staphylococcus aureus (MRSA) often requires surgery and prolonged systemic antibiotic treatment. Local antibiotic delivery systems of bioceramics or polymers have been developed to treat osteomyelitis. A disadvantage of biodegradable polymers is the initial burst of antibiotics into the environment; one advantage of bioceramics is its osteoconductivity. We therefore developed a vancomycin-containing poly-l-lactic acid/beta-tricalcium phosphate (PLLA/beta-TCP) composite to control antibiotic release and stimulate bone formation.

Subject Keywords

Orthopedics and Sports Medicine, General Medicine

URI

https://hdl.handle.net/11511/56993

Collections

Graduate School of Natural and Applied Sciences, Article